TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus

Degenerative aortic stenosis (AS) is the most common valve condition. A significant number of AS patients presents a small aortic annulus (SAA), especially women. Treating this group of patients remains challenging, seeing as they have a high incidence of suboptimal hemodynamic results.  Despite the development of TAVR (transcatheter aortic valve replacement), the current guidelines do<a href="https://solaci.org/en/2023/10/31/tct-2023-viva-trial-tavr-vs-savr-in-patients-with-severe-aortic-stenosis-and-small-aortic-annulus/" title="Read more" >...</a>

TCT 2023 | ALIGN AR Trial

Dr. Thourani has presented the ALIGN AR, a single arm, multicenter and non-blinded trial on the use of JenaValve in symptomatic patients with severe aortic regurgitation and high surgical risk.  Safety primary end point was a composite variables including all-cause mortality at 30 days, stroke, major bleeding, vascular complications, kidney failure, need for definite pacemaker<a href="https://solaci.org/en/2023/10/30/tct-2023-align-ar-trial-2/" title="Read more" >...</a>

TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up

In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement (TAVR) in younger patients, with an average age of 74 years, as observed in US medical records. This trend goes alongside encouraging durability results, as demonstrated in the 10-year NOTION study, where structural valve degeneration (SVD) with first-generation<a href="https://solaci.org/en/2023/10/27/tct-2023-evolut-low-risk-4-year-follow-up/" title="Read more" >...</a>

Sedación consciente vs anestesia general en el TAVI

Cause of Cardiac Death after TAVR at Present

Cardiac failure (CF) and sudden cardiac death (SCD) stand out as two of the main causes of death in patients with aortic stenosis. Although transcatheter aortic valve intervention has shown higher survival, these two continue to be the main conditions leading to patient death at followup.  In its early days, TAVR also showed benefits, but<a href="https://solaci.org/en/2023/10/11/cause-of-cardiac-death-after-tavr-at-present/" title="Read more" >...</a>

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

TriClip: Good Outcomes After a 2-Year Follow-up

Severe tricuspid regurgitation (TR) is an underestimated condition in healthcare systems. However, it is more common than believed, especially in individuals over 65 years of age.  This condition is linked to hospitalizations due to heart failure, mortality rates, and a progressive decline in quality of life.  Surgery to treat TR on its own is complicated,<a href="https://solaci.org/en/2023/10/04/triclip-good-outcomes-after-a-2-year-follow-up/" title="Read more" >...</a>

MIL Training More MIL – Day 4: Favaloro Foundation

The program MIL Training More MIL continues in specialized centers in Buenos Aires. Yesterday it took place at the prestigious Favaloro Foundation. During the session, Dr. Fava, interventional cardiologist from the foundation, delivered talks together with the grant holding physicians on MItraclip, Evidence in Cusp Overlap, Pacemaker Risks in Self-Expandable TAVR, Coronary Artery Disease and<a href="https://solaci.org/en/2023/10/02/mil-training-more-mil-day-4-favaloro-foundation/" title="Read more" >...</a>

TRILUMINATE Two Years In: Encouraging Results

Tricuspid valve regurgitation is more common than one might think. It often stems from left valve disease and associated with increased mortality and hospitalization due to heart failure, which is not easy to treat. Currently, guidelines list surgery as the recommended treatment, though this option is quite complex and might entail complications and mortality risk.<a href="https://solaci.org/en/2023/09/19/triluminate-two-years-in-encouraging-results/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

TAVI-in-TAVI with Balloon-Expandable Valves

TAVI (Transcatheter Aortic Valve Implantation) has proven to be beneficial and is currently performed in increasingly younger and lower-risk patients. However, as with surgical bioprostheses, structural deterioration, whether due to stenosis or regurgitation, is one of the challenges we must address.  While currently uncommon, this is an issue we will probably see more and more<a href="https://solaci.org/en/2023/09/12/tavi-in-tavi-with-balloon-expandable-valves/" title="Read more" >...</a>

Predictors and Evolution of Need for PPM after TAVR with Self-Expanding Valves

In the context of TAVR, one of the current challenges is the need for permanent pacemaker implantation (PPM), especially when using self-expanding valves (SEV). The information available in this regard remains controversial; while some studies suggest new PPM implantation will have no significant effect on clinical evolution, others have associated them with worse prognosis.  As<a href="https://solaci.org/en/2023/09/06/predictors-and-evolution-of-need-for-ppm-after-tavr-with-self-expanding-valves/" title="Read more" >...</a>

ESC 2023 | BUDAPEST CRT Upgrade trial

Approximately 1 million pacemakers (PM) or Implantable cardioverter-defibrillators (ICDs) are placed every year around the world, and it has been observed that 30% of these cases present left ventricular dysfunction, mainly systolic. This dysfunction is attributed to PM induced right ventricle dyssynchrony, which in time leads to hospitalization for cardiac failure and increased clinical adverse<a href="https://solaci.org/en/2023/08/29/esc-2023-budapest-crt-upgrade-trial-2/" title="Read more" >...</a>

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31